未知生产厂商
Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.
Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
